Predicting Benefit From Olaparib Maintenance in Metastatic Pancreatic Cancer: The POLO Trial

based on outcomes from the POLO trial,1,2 the BRACAnalysis CDx assay (Myriad Genetics) become capable of perceiving patients with metastatic pancreatic cancer who benefitted from upkeep therapy with the poly [ADP ribose] polymerase (PARP) inhibitor olaparib, in step with press announcements launched on February 26, 2019.1, three

The POLO have a look at is a section 3, randomized, managed trial of olaparib monotherapy in 154 patients with metastatic pancreatic adenocarcinoma (with ailment that had no longer improved following first-line platinum-based totally chemotherapy) who have been randomly assigned (three:2) to get hold of two times-each day management of 300 mg of olaparib or placebo.1,2

All patients who had been enrolled in the look at had a deleterious or suspected deleterious germline BRCA1/2 mutation diagnosed through the BRACAnalysis CDx assay. The number one gives up the point of the POLO trial became development-loose survival, with normal survival, normal response rate, safety, and health-associated best of lifestyles covered as secondary give up factors.

Results from the POLO trial confirmed that it met its primary end factor of statistically drastically improvement in PFS while the olaparib arm became as compared with the placebo arm. Also, the protection and tolerability profiles of olaparib have been much like effects determined in previous trials of this agent in other cancers.1

“This is the first high-quality segment three trial of any PARP inhibitor in germline BRCA-mutated metastatic pancreatic most cancers, a devastating ailment with essential unmet need. The results of POLO also provide proof of the scientific gain of [olaparib] throughout a selection of BRCA-mutated tumor types. We will discuss these results with worldwide fitness authorities as quickly as feasible,” stated José Baselga, govt vice president, research and improvement, oncology at AstraZeneca.

The BRACAnalysis CDx take a look at has formerly received approval from the United States Food and Drug Administration (FDA) as an associate diagnostic assay for identifying patients with advanced breast and ovarian cancers who are applicants for the PARP inhibitor, olaparib. Three

References

AstraZeneca. Lynparza drastically behind schedule disorder progression as 1st-line protection remedy in germline BRCA-mutated metastatic pancreatic cancer [press release]. Published on February 26, 2019. Accessed February 28, 2019.
ClinicalTrials.Gov Identifier: NCT02184195. Olaparib in gBRCA mutated pancreatic cancer whose disorder has now not progressed on first line platinum-based chemotherapy (POLO). Updated January 29, 2019. Accessed February 28, 2019.
Myriad. Myriad’s BRACAnalysis CDx® takes a look at successfully recognized patients with metastatic pancreatic cancer who benefitted from treatment with olaparib [press release]. Published on February 26, 2019. Accessed February 28, 2019.